1
|
Penrod D, Hirsch B. Nursing Care for Metastatic Bone Cancer: Trends for the Future. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:6483. [PMID: 37569024 PMCID: PMC10418383 DOI: 10.3390/ijerph20156483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 07/20/2023] [Accepted: 07/27/2023] [Indexed: 08/13/2023]
Abstract
To effectively treat patients and minimize viral exposure, oncology nurses and radiology departments during COVID-19 had to re-examine the ability to offer palliative radiation treatments to people with metastatic bone cancer. Decreasing potential exposure to the virus resulted in extra measures to keep patients and personnel safe. Limiting radiotherapy treatments, social distancing, and limiting caregivers were a few of the ways that oncology patients were impacted by the pandemic. Hypofractionated radiation therapy (HFRT), or the delivery of fewer higher-dose treatments, was a method of providing care but also limiting exposure to infection for immunocompromised patients as well as healthcare staff. As oncology radiation centers measure the impact of patient care during the pandemic, a trend toward HFRT may occur in treating the painful symptoms of bone cancer. In anticipation that HFRT may be increasingly used in patient treatment plans, oncology nurses should consider patient perspectives and outcomes from the pandemic to further determine how to manage future trends in giving personalized care, and supportive care.
Collapse
Affiliation(s)
- Debra Penrod
- Nursing, School of Health Sciences, Southern Illinois University, Carbondale, IL 62901, USA
| | - Brandon Hirsch
- Radiological Sciences, School of Health Sciences, Southern Illinois University, Carbondale, IL 62920, USA;
| |
Collapse
|
2
|
Cozzi S, Ruggieri MP, Bardoscia L, Najafi M, Blandino G, Giaccherini L, Manicone M, Ramundo D, Rosca A, Solla DS, Botti A, Lambertini D, Ciammella P, Iotti C. Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience. J Cancer Res Ther 2023; 19:644-649. [PMID: 37470588 DOI: 10.4103/jcrt.jcrt_529_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/21/2023]
Abstract
BACKGROUND After coronavirus disease outbreak emerged in 2019, radiotherapy departments had to adapt quickly their health system and establish new organizations and priorities. The purpose of this work is to report our experience in dealing with COVID-19 emergency, how we have reorganized our clinical activity, changed our priorities, and stressed the use of hypofractionation in the treatment of oncological diseases. MATERIALS AND METHODS The patients' circuit of first medical examinations and follow-up was reorganized; a more extensive use of hypofractionated schedules was applied; a daily triage of the patients and staff, use of personal protective equipment, hand washing, environment sanitization, social distancing and limitations for the patients' caregivers in the department, unless absolutely essential, were performed; patients with suspected or confirmed COVID-19 were treated at the end of the day. In addition, the total number of radiotherapy treatment courses, patients and sessions, in the period from February 15 to April 30, 2020, comparing the same time period in 2018 were retrospectively investigated. In particular, changes in hypofractionated schedules adopted for the treatment of breast and prostate cancer and palliative bone metastasis were analyzed. RESULTS Between February 15, and April 30, 2020, an increased number of treatments was carried out: Patients treated were overall 299 compared to 284 of the same period of 2018. Stressing the use of hypofractionation, 2036 RT sessions were performed, with a mean number of fractions per course of 6.8, compared to 3566 and 12.6, respectively, in 2018. For breast cancer, the schedule in 18 fractions has been abandoned and treatment course of 13 fractions has been introduced; a 27% reduction in the use of 40.5 Gy in 15 fractions, (67 treatments in 2018-49 in 2020) was reported. An increase of 13% of stereotactic body radiation therapy for prostate cancer was showed. The use of the 20 Gy in 4 or 5 sessions for the treatment of symptomatic bone metastasis decreased of 17.5% in favor of 8 Gy-single fraction. Three patients results COVID-19 positive swab: 1 during, 2 after treatment. Only one staff member developed an asymptomatic infection. CONCLUSIONS The careful application of triage, anti-contagion and protective measures, a more extensive use of hypofractionation allowed us to maintain an effective and continuous RT service with no delayed/deferred treatment as evidenced by the very low number of patients developing COVID-19 infection during or in the short period after radiotherapy. Our experience has shown how the reorganization of the ward priority, the identification of risk factors with the relative containment measures can guarantee the care of oncological patients, who are potentially at greater risk of contracting the infection.
Collapse
Affiliation(s)
- Salvatore Cozzi
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Maria Paola Ruggieri
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Lilia Bardoscia
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Masoumeh Najafi
- Department of Radiation Oncology Shohadaye Haft-e-Tir Hospital, Iran University of Medical Science, Teheran, Iran
| | - Gladys Blandino
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Lucia Giaccherini
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Moana Manicone
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Dafne Ramundo
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Ala Rosca
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Dario Salvatore Solla
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Andrea Botti
- Medical Physics Unit, Department of Oncology and Advanced technology, AUSL-IRCCS di Reggio Emilia, Italy
| | - Daniele Lambertini
- Medical Physics Unit, Department of Oncology and Advanced technology, AUSL-IRCCS di Reggio Emilia, Italy
| | - Patrizia Ciammella
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| | - Cinzia Iotti
- Radiation Therapy Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Italy
| |
Collapse
|
3
|
Piras A, Venuti V, D’Aviero A, Cusumano D, Pergolizzi S, Daidone A, Boldrini L. Covid-19 and radiotherapy: a systematic review after 2 years of pandemic. Clin Transl Imaging 2022; 10:611-630. [PMID: 35910079 PMCID: PMC9308500 DOI: 10.1007/s40336-022-00513-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 07/12/2022] [Indexed: 02/08/2023]
Abstract
Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role.Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was "Covid AND Radiotherapy" and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.
Collapse
Affiliation(s)
- Antonio Piras
- Radioterapia Oncologica, Villa Santa Teresa, Palermo, Italy
| | - Valeria Venuti
- Radioterapia Oncologica, Università degli Studi di Palermo, Palermo, Italy
| | - Andrea D’Aviero
- Radiation Oncology, Mater Olbia Hospital, Olbia, Sassari Italy
| | | | - Stefano Pergolizzi
- Radiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy
| | | | - Luca Boldrini
- Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, UOC Radioterapia Oncologica - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- Università Cattolica del Sacro Cuore, Roma, Italy
| |
Collapse
|
4
|
Venkatasai J, John C, Kondavetti SS, Appasamy M, Parasuraman L, Ambalathandi R, Masilamani H. Impact of COVID-19 Pandemic on Patterns of Care and Outcome of Head and Neck Cancer: Real-World Experience From a Tertiary Care Cancer Center in India. JCO Glob Oncol 2022; 8:e2100339. [PMID: 35213235 PMCID: PMC8887950 DOI: 10.1200/go.21.00339] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The COVID-19 pandemic has caused unprecedented health, social, and economic unrest globally, particularly affecting resource-limited low-middle–income countries. The resultant curfew had made the access to and delivery of cancer care services an arduous task. We have reported the patterns of care and 1-year outcome of head and neck squamous cell carcinoma (HNSCC) treatment before and during COVID-19 lockdown at our institution. COVID-19 restrictions can have adverse impact on the access to and delivery of RT #HNCSM #COVID19![]()
Collapse
Affiliation(s)
- Jeyaanth Venkatasai
- Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Christopher John
- Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Satish Srinivas Kondavetti
- Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Mallika Appasamy
- Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | | | - Ravichandran Ambalathandi
- Department of Medical Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Hemavathi Masilamani
- Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| |
Collapse
|
5
|
Kusiak A, Cichońska D, Tubaja M, Skorek A, Jereczek-Fossa BA, Corrao G, Marvaso G, Alterio D. COVID-19 manifestation in the oral cavity - a narrative literature review. ACTA ACUST UNITED AC 2021; 41:395-400. [PMID: 34734574 PMCID: PMC8569657 DOI: 10.14639/0392-100x-n1584] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 06/11/2021] [Indexed: 12/15/2022]
Abstract
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently discovered coronavirus, which in 2020 led to a global pandemic. Clinical manifestations of COVID-19 are very diverse and symptoms range from mild to severe. Correlated symptoms might also manifest in the oral cavity, which is a potential pathway for viral infection, and therefore might be a potential pathway for SARS-CoV-2. In recent research among patients with SARS-CoV-2 infection, taste and olfactory disorders, dry mouth, drones and inflammation of mouth, bitter taste in mouth, difficulty in swallowing and burning sensations have been reported. There have been cases of oral mucosal lesions in patients diagnosed with COVID-19 disease. Some correlations between periodontitis and severity of COVID-19 disease have also been observed. Oral mucosa, due to occurrence of ACE2 receptors, is highly susceptible to SARS-CoV-2 infection. The occurrence of changes on oral mucosa should increase the alertness of dental practitioners. However, knowledge in this area is still limited and in the field of oral manifestations of COVID-19 more research and patient observations are required.
Collapse
Affiliation(s)
- Aida Kusiak
- Department of Periodontology and Oral Mucosa Diseases, Medical University of Gdansk, 80-210 Gdansk, Poland
| | - Dominika Cichońska
- Department of Periodontology and Oral Mucosa Diseases, Medical University of Gdansk, 80-210 Gdansk, Poland
| | - Monika Tubaja
- Department of Periodontology and Oral Mucosa Diseases, Medical University of Gdansk, 80-210 Gdansk, Poland
| | - Andrzej Skorek
- Department of Otolaryngology, Medical University of Gdansk, 80-210 Gdansk, Poland
| | - Barbara Alicja Jereczek-Fossa
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.,Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - Giulia Corrao
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.,Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - Giulia Marvaso
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.,Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - Daniela Alterio
- Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy
| |
Collapse
|
6
|
Galofaro E, Malizia C, Ammendolia I, Galuppi A, Guido A, Ntreta M, Siepe G, Tolento G, Veraldi A, Scirocco E, Arcelli A, Buwenge M, Ferioli M, Zamagni A, Strigari L, Cammelli S, Morganti AG. COVID-19 Pandemic-Adapted Radiotherapy Guidelines: Are They Really Followed? Curr Oncol 2021; 28:3323-3330. [PMID: 34590595 PMCID: PMC8482258 DOI: 10.3390/curroncol28050288] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 08/18/2021] [Accepted: 08/23/2021] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND In our department, we provided guidelines to the radiation oncologists (ROs) regarding the omission, delay, or shortening of radiotherapy (RT). The purpose was to reduce the patients' exposure to the hospital environment and to minimize the departmental overcrowding. The aim was to evaluate the ROs' compliance to these guidelines. METHODS ROs were asked to fill out a data collection form during patients' first visits in May and June 2020. The collected data included the ROs' age and gender, patient age and residence, RT purpose, treated tumor, the dose and fractionation that would have been prescribed, and RT changes. The chi-square test and binomial logistic regression were used to analyze the correlation between the treatment prescription and the collected parameters. RESULTS One hundred and twenty-six out of 205 prescribed treatments were included in this analysis. Treatment was modified in 61.1% of cases. More specifically, the treatment was omitted, delayed, or shortened in 7.9, 15.9, and 37.3% of patients, respectively. The number of delivered fractions was reduced by 27.9%. A statistically significant correlation (p = 0.028) between younger patients' age and lower treatment modifications rate was recorded. CONCLUSION Our analysis showed a reasonably high compliance of ROs to the pandemic-adapted guidelines. The adopted strategy was effective in reducing the number of admissions to our department.
Collapse
Affiliation(s)
- Elena Galofaro
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
- Correspondence: ; Tel.: +39-3409328999
| | - Claudio Malizia
- Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;
| | - Ilario Ammendolia
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Andrea Galuppi
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Alessandra Guido
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Maria Ntreta
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Giambattista Siepe
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Giorgio Tolento
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Antonio Veraldi
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
| | - Erica Scirocco
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Alessandra Arcelli
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Milly Buwenge
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Martina Ferioli
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Alice Zamagni
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Lidia Strigari
- Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;
| | - Silvia Cammelli
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| | - Alessio Giuseppe Morganti
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; (I.A.); (A.G.); (A.G.); (M.N.); (G.S.); (G.T.); (A.V.); (E.S.); (A.A.); (M.B.); (M.F.); (A.Z.); (S.C.); (A.G.M.)
- Department of Experimental, Diagnostic, and Specialty Medicine—DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
| |
Collapse
|
7
|
Magrini SM, Guerini AE, Borghetti P, Volpi G, Triggiani L, Costa L, Pegurri L, Spiazzi L, Buglione M. Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia. TUMORI JOURNAL 2021; 108:278-282. [PMID: 34405756 DOI: 10.1177/03008916211034917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The impact of coronavirus disease 2019 (COVID-19) has been overwhelming on patients with cancer, who may be at higher risk of developing severe disease. During the second COVID-19 outbreak in Italy, we planned universal microbiologic screening for patients scheduled for antineoplastic treatment. METHODS All patients with planned active treatment at Brescia University Radiation Oncology Department were screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA with repeated nasopharyngeal swabs (NPS) from October 31, 2020. Treatment continuation, suspension, or delay was modulated for patients testing positive according to clinical presentation. RESULTS From October 31, 2020, to February 6, 2021, 636 patients were enrolled and 1243 NPS were performed, of which 28 (2.25%) were positive. The infection rate was 2.52%; 81.3% of the patients with a positive NPS were asymptomatic, 2 had mild disease, and 1 severe disease that led to death. All patients already on treatment with mild or asymptomatic COVID-19 carried on the therapy with no or minimal delay. Median delay for patients with infection detected before treatment start was 16.5 days. CONCLUSIONS Detected incidence of COVID-19 was lower during the second outbreak in our patients (2.52% vs 3.23%), despite the extensive testing schedule, and substantiates the high rate of asymptomatic infections and the low mortality among patients with COVID-19 (6.3% vs 38.5% during the first outbreak). Universal SARS-CoV-2 screening for all patients with planned treatment might allow early identification of patients with COVID-19, resulting in timely management that could improve clinical outcomes and prevent spread of the infection.
Collapse
Affiliation(s)
- Stefano M Magrini
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Andrea E Guerini
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Paolo Borghetti
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Giulia Volpi
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Luca Triggiani
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| | - Loredana Costa
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Ludovica Pegurri
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Luigi Spiazzi
- Department of Radiation Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Michela Buglione
- Department of Radiation Oncology, Università degli Studi di Brescia, Brescia University, Brescia, Italy
| |
Collapse
|
8
|
Miura H, Hioki K, Ozawa S, Kanemoto K, Nakao M, Doi Y, Kenjo M, Nagata Y. Uncertainty in the positioning of patients receiving treatment for brain metastases and wearing surgical mask underneath thermoplastic mask during COVID-19 crisis. J Appl Clin Med Phys 2021; 22:274-280. [PMID: 34028970 PMCID: PMC8200509 DOI: 10.1002/acm2.13279] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 04/15/2021] [Accepted: 04/20/2021] [Indexed: 12/26/2022] Open
Abstract
Thermoplastic masks, used along with surgical masks, enable immobilization methods to reduce the risk of infection in patients undergoing intracranial stereotactic radiosurgery and stereotactic radiotherapy (SRS/SRT) during the COVID‐19 crisis. The purpose of this study was to investigate the feasibility of thermoplastic mask immobilization with a surgical mask using an ExacTrac system. Twelve patients each with brain metastases were immobilized using a thermoplastic mask and a surgical mask and only a thermoplastic mask. Two x‐ray images were acquired to correct (XC) and verify (XV) the patient’s position at a couch angle of 0°. Subsequently, the XC and XV images were acquired at each planned couch angle for non‐coplanar beams. When the position errors were detected after couch rotation for non‐coplanar beams, the errors were corrected at each planned couch angle until a clinically acceptable tolerance was attained. The position errors in the translational and rotational directions (vertical, lateral, longitudinal, pitch, roll, and yaw) were retrospectively investigated using data from the ExacTrac system database. A standard deviation of XC translational and rotational position errors with and without a surgical mask in the lateral (1.52 vs 2.07 mm), longitudinal (1.59 vs 1.87 mm), vertical (1.00 vs 1.73 mm), pitch (0.99 vs 0.79°), roll (1.24 vs 0.68°), and yaw (1.58 vs 0.90°) directions were observed at a couch angle of 0°. Most of patient positioning errors were less than 1.0 mm or 1.0° after the couch was rotated to the planned angle for non‐coplanar beams. The overall absolute values of the translational and rotational XV position errors with and without the surgical mask were less than 0.5 mm and 0.5°, respectively. This study showed that a thermoplastic mask with a surgical mask is a feasible immobilization technique for brain SRS/SRT patients using the ExacTrac system.
Collapse
Affiliation(s)
- Hideharu Miura
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| | - Kazunari Hioki
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan
| | - Shuichi Ozawa
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| | - Kenji Kanemoto
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan
| | - Minoru Nakao
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| | - Yoshiko Doi
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| | - Masahiko Kenjo
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| | - Yasushi Nagata
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, 732-0057, Japan.,Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 739-8511, Japan
| |
Collapse
|
9
|
Alarcón MA, Sanz-Sánchez I, Shibli JA, Treviño Santos A, Caram S, Lanis A, Jiménez P, Dueñas R, Torres R, Alvarado J, Avendaño A, Galindo R, Umanzor V, Shedden M, Invernizzi C, Yibrin C, Collins J, León R, Contreras L, Bueno L, López-Pacheco A, Málaga-Figueroa L, Sanz M. Delphi Project on the trends in Implant Dentistry in the COVID-19 era: Perspectives from Latin America. Clin Oral Implants Res 2021; 32:521-537. [PMID: 33595844 PMCID: PMC8014337 DOI: 10.1111/clr.13723] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 01/13/2021] [Accepted: 02/08/2021] [Indexed: 02/07/2023]
Abstract
AIM To establish trends in Implant Dentistry in Latin America in the COVID-19 pandemic. MATERIAL AND METHODS A steering committee and an advisory group of experts in Implant Dentistry were selected among eighteen countries. An open-ended questionnaire by Delphi methodology was validated including 64 questions, divided in 7 topics, concerning the various trends in dental implantology. The survey was conducted in two rounds, which provided the participants in the second round with the results of the first. The questionnaires were completed on August 2020, and the online meeting conference was held on September 2020. The final prediction was developed through consensus by a selected group of experts. RESULTS A total of 197 experts from Latin America answered the first and second questionnaire. In the first round, the established threshold for consensus (65%) was achieved in 30 questions (46.87%). In the second round, performed on average 45 days later, this level was achieved in 47 questions (73.43%). Consensus was completely reached on the item "Diagnostic" (100%), the field with the lowest consensus was "Demand for treatment with dental implants" (37.5%). CONCLUSIONS The present study in Latin America has provided relevant and useful information on the predictions in the education and practice of Implant Dentistry in the COVID-19 era. The consensus points toward a great confidence of clinicians in the biosecurity protocols used to minimize the risk of SARS-CoV-2 transmission. It is foreseen as an important change in education, with introduction of virtual reality and other simulation technologies in implant training.
Collapse
Affiliation(s)
- Marco Antonio Alarcón
- PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Cayetano Heredia Peruvian University, Lima, Perú
| | - Ignacio Sanz-Sánchez
- ETEP (Etiology and Therapy of Periodontal and Peri-Implant Diseases) Research Group, University Complutense, Madrid, Spain
| | - Jamil Awad Shibli
- Department of Periodontology and Oral Implantology, Dental Research Division, Guaruhos University, Guarulhos, SP, Brazil
| | - Alejandro Treviño Santos
- Postgraduate Studies and Research Division, Faculty of Dentistry, National Autonomous University of Mexico, UNAM, Mexico City, Mexico
| | | | - Alejandro Lanis
- Private Practice, Santiago, Chile.,Department of Prosthodontics, Indiana University School of Dentistry, Indianapolis, IN, USA
| | | | - Ricardo Dueñas
- Centro de Investigaciones Odontológicas, School of Dentistry, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Ronald Torres
- Department of Diagnostic and Surgical Sciences, Faculty of Dentistry, University of Costa Rica, San José, Costa Rica
| | - Jacinto Alvarado
- Research Group GIRO, Department of Periodontology, University of Cuenca, Cuenca, Ecuador
| | | | - Roberto Galindo
- Posgraduate Periodontology and Oral Implantology, Universidad Francisco Marroquín, Ciudad de Guatemala, Guatemala
| | - Vilma Umanzor
- Periodontics and Implant Dentistry, Department of Social/Prevention, School of Dentistry, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras
| | | | - Carlos Invernizzi
- Department of Research in Dentistry, Autonomous University of Asunción, Asunción, Paraguay
| | - Caroll Yibrin
- Universidad Central de Venezuela, Caracas, Venezuela
| | - James Collins
- Department of Periodontology, School of Dentistry, Pontificia Universidad Católica Madre y Maestra, Santo Domingo, Dominican Republic
| | - Roberto León
- Public Health and Dentistry Services Management Research Unit, Cayetano Heredia Peruvian University, Lima, Perú
| | | | - Luis Bueno
- Periodontics Department, School of Dentistry, Universidad de la República, Montevideo, Uruguay
| | - Andrea López-Pacheco
- PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Section of Oral Implantology, Cayetano Heredia Peruvian University, Lima, Perú
| | - Lilian Málaga-Figueroa
- PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Cayetano Heredia Peruvian University, Lima, Perú
| | - Mariano Sanz
- ETEP (Etiology and Therapy of Periodontal and Peri-Implant Diseases) Research Group, University Complutense, Madrid, Spain
| |
Collapse
|
10
|
Svajdova M, Sicak M, Dubinsky P, Slavik M, Slampa P, Kazda T. Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic. Cancers (Basel) 2020; 12:cancers12123510. [PMID: 33255751 PMCID: PMC7760235 DOI: 10.3390/cancers12123510] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 11/22/2020] [Accepted: 11/23/2020] [Indexed: 12/24/2022] Open
Abstract
Simple Summary Options for the curative treatment of locally recurrent nasopharyngeal carcinoma include surgery or re-irradiation. Both approaches have been scientifically explored, yet there is no consensus on the indication or definitive preference of the above two salvage treatments. The aim of this review is to summarize the current evidence on the local treatment of recurrent nasopharyngeal carcinoma. The feasibility, safety, and efficacy of salvage surgery and radical re-irradiation are discussed. Recommendations on treatment modifications during the coronavirus disease 2019 pandemic are included as well. Abstract Recurrent nasopharyngeal carcinoma represents an extremely challenging therapeutic situation. Given the vulnerability of the already pretreated neurological structures surrounding the nasopharynx, any potential salvage retreatment option bears a significant risk of severe complications that result in high treatment-related morbidity, quality of life deterioration, and even mortality. Yet, with careful patient selection, long-term survival may be achieved after local retreatment in a subgroup of patients with local or regional relapse of nasopharyngeal cancer. Early detection of the recurrence represents the key to therapeutic success, and in the case of early stage disease, several curative treatment options can be offered to the patient, albeit with minimal support in prospective clinical data. In this article, an up-to-date review of published evidence on modern surgical and radiation therapy treatment options is summarized, including currently recommended treatment modifications of both therapeutic approaches during the coronavirus disease 2019 pandemic.
Collapse
Affiliation(s)
- Michaela Svajdova
- Department of Radiation and Clinical Oncology, Central Military Hospital—Teaching Hospital Ruzomberok, 034 01 Ruzomberok, Slovakia
- Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic;
- Correspondence: ; Tel.: +421-911-618-265
| | - Marian Sicak
- Department of Otorhinolaryngology and Head and Neck Surgery, Central Military Hospital—Teaching Hospital, 034 01 Ruzomberok, Slovakia;
| | - Pavol Dubinsky
- Department of Radiation Oncology, East Slovakia Oncology Institute, 041 91 Kosice, Slovakia;
- Faculty of Health, Catholic University Ruzomberok, 034 01 Ruzomberok, Slovakia
| | - Marek Slavik
- Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic;
- Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic; (P.S.); (T.K.)
| | - Pavel Slampa
- Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic; (P.S.); (T.K.)
| | - Tomas Kazda
- Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic; (P.S.); (T.K.)
| |
Collapse
|